BBIO vs CE · rev $221.9M vs rev $10.28B
BridgeBio Pharma Inc (BBIO) versus Celanese Corporation (CE) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Celanese Corporation (CE) is a chemicals company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
BBIO currently screens at market cap $13.24B. CE currently screens at market cap $5.92B.
Not investment advice. Open the BBIO and CE stock pages for the full models.
Not investment advice.